Regulatory updates, research developments, and peptide industry insights
The FDA has officially scheduled Pharmacy Compounding Advisory Committee meetings for July 23-24, 2026 to evaluate seven peptides including BPC-157, TB-500, KPV, and MOTS-C for potential reclassification.
Read ArticleHHS Secretary Kennedy has directed the FDA to reclassify 12 peptides from Category 2 back to Category 1, reversing the 2023 Biden-era restrictions. Here is what it means for the research community.
Read ArticleA clear breakdown of how the FDA classifies peptides under Section 503A, what each category means, and why it matters for researchers and the peptide industry.
Read ArticleNeogenesis Bio Labs
Your first order. Enter your email and we'll
send your code instantly.
Research professionals only • Unsubscribe anytime